SAT0235 BIIB059, a monoclonal antibody targeting BCDA2 shows safety, tolerability, pharmacokinetics, pharmacodynamics in healthy volunteer subjects

• Published in: Annals of the rheumatic diseases Vol. 76; no. Suppl 2; p. 862
• Main Authors: Martin, D, Stevenson, L, Prasad, P, Smirnakis, K, Kao, A, Rabah, D, Wang, W, Barbey, C, Musselli, C, Franchimont, N
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 01.06.2017
• Subjects: Bioavailability; Cell surface; Dendritic cells; Drug dosages; EKG; Enzyme-linked immunosorbent assay; Flow cytometry; Inflammation; Interferon; Internalization; Monoclonal antibodies; Pharmacodynamics; Pharmacokinetics; Safety; Stockholders; Systemic lupus erythematosus

BackgroundType I interferons (IFN-I) are central to the pathogenesis of systemic lupus erythematosus (SLE). BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, upon engagement, inhibits the production of IFN-I and other inflammatory mediators. Targeting BDCA2 therefore represents an...